Strategic Board Additions ILiAD has recently bolstered its leadership with high-profile board appointments including executives from Vaxcyte, Cidara, and Sanofi Vaccines, signaling a reinforced capability to advance toward pivotal phase trials and potential partnerships. This presents an opportunity to engage investors, partners, and contract research organizations aligned with a broader vaccine development and commercialization strategy.

BPZE1 Focus The company is actively developing BPZE1 and other Bordetella pertussis technologies, positioning ILiAD as a specialized partner for pertussis prevention and related respiratory disease programs. This opens doors for collaborations in clinical development services, manufacturing partnerships, and co-development deals around intranasal vaccine platforms.

Commercial Leadership With Antony Blanc joining as Chief Business Officer and a background in global marketing and pricing at GSK Vaccines, ILiAD is strengthening its market access and pricing strategy. This creates opportunities for advisory services, market access partnerships, and strategic commercialization planning for late-stage vaccines.

Funding Momentum A sizeable Series B of 115 million and an overall funding of 183 million indicate strong investor confidence and readiness to scale operations, clinical trials, and manufacturing capabilities. Potential partnerships could target co-development, strategic investments, and rights of first negotiation for future assets.

Clinical Trial Collaboration A potential pivotal phase three human challenge trial with hVivo suggests openness to strategic partnerships for trial design, operational support, and trial sites. This presents a pathway for specialized CRO engagement, outsourcing partnerships, and joint-venture opportunities to accelerate regulatory approval.